Yestar Healthcare Holdings Co Ltd 2017 AR2
The report highlights Yestar Healthcare Holdings Company Limited's financial and operational performance for the fiscal year 2017. The company achieved a 30% increase in overall revenue to RMB 3,926.9 million, driven by the expansion of its In-Vitro Diagnostics (IVD) distribution network, including the acquisition of Beijing Kaihongda. Yestar also diversified downstream by establishing the Shanghai Zhongke Runda Medical Laboratory. On the sustainability front, the company published its second ESG report, detailing its efforts in quality assurance, environmental protection, and community investment, while maintaining zero work-related fatalities.
Company: Yestar Healthcare Holdings Co Ltd
Sector: Health Care
Country: China
Year: 2017
Type: AR2
Pages: 164
Yestar Healthcare Holdings Co Ltd
Annual Report
The report highlights Yestar Healthcare Holdings Company Limited's financial and operational performance for the fiscal year 2017. The company achieved a 30% increase in overall revenue to RMB 3,926.9 million, driven by the expansion of its In-Vitro Diagnostics (IVD) distribution network, including the acquisition of Beijing Kaihongda. Yestar also diversified downstream by establishing the Shanghai Zhongke Runda Medical Laboratory. On the sustainability front, the company published its second ESG report, detailing its efforts in quality assurance, environmental protection, and community investment, while maintaining zero work-related fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees